A1150 NALOXONE PROGRAM (002).DOCX

MARICOPA COUNTY INTERNAL POLICY
Policy Number:
A1150
Current Adoption Date:
MM-DD-YYYY
Policy Title:
NALOXONE PROGRAM
Current Implementation Date:
MM-DD-YYYY
Board Agenda Number:
C-##-##-###-#-##
Approved by:
BOARD OF SUPERVISORS
Original Adoption Date:
MM-DD-YYYY
I. PURPOSE
To provide general guidelines for County employees, contractors, and non-employee volunteers who 
participate in the County’s Naloxone Program to obtain Naloxone, be trained in the administration of 
Naloxone, and voluntarily Administer Naloxone to an individual during a perceived medical emergency if 
necessary.
II. APPLICATION
This Policy applies to all Maricopa County appointed departments and the Flood Control District of Maricopa 
County, the Maricopa County Library District, and the Maricopa County Stadium District (Special Districts). 
The Board of Supervisors is authorized to jointly adopt policies applying to the Special Districts under the 
Intergovernmental Agreement, C-06-18-393-6-00, approved on April 11, 2018.
This policy also applies to employees of County elected offices unless the elected official has implemented 
a similar policy specific to his or her office.
III. DEFINITIONS
A.
Administer: The direct application of a drug into the body of an individual by injection, inhalation, 
ingestion, or by other means. For the purposes of this program, administration of Naloxone or NARCAN® 
will only occur via intranasal application.  
B.
Department Designee: Individuals who are authorized within County departments who will assist with 
ordering, maintaining documentation, and providing information to the Program Coordinator.
C.
Distribute: The provision of Naloxone Kits to County Departments and Participants who are authorized 
to Possess Naloxone and Administer the medication voluntarily to people in need.
D.
Naloxone: The generic name for medication that can be used to reverse the effects of an opiate overdose. 
Specifically, it displaces Opioids from the receptors in the brain that control the central nervous and 
respiratory systems. It is marketed under various trademarks, including NARCAN®. For the purposes of 
this policy, NARCAN® and Naloxone may be used interchangeably. 
E.
Naloxone Kit: A Naloxone Kit includes a carrying case with two doses of nasal NARCAN®, instructions 
for the administration of NARCAN®, a short list of emergency assistance programs, and gloves. 
F.
NARCAN® (Naloxone HCI) Nasal Spray: A medicine used for the treatment of an Opioid emergency. 
Specifically, it displaces Opioids from the receptors in the brain that control the central nervous and 
respiratory systems. Although NARCAN® (Naloxone HCI) Nasal Spray is safe and effective in adults and 
children for known or suspected Opioid Overdose, it does not take the place of emergency medical care. 
G. Naloxone Program: The Maricopa County initiative allowing employees, contractors, and non-employee 
volunteers who have been properly trained to Possess and Administer Naloxone voluntarily to persons 
in need.

Policy Number:
A1150
Policy Title:
NALOXONE PROGRAM
Current Adoption Date:
MM-DD-YYYY
Page 2 of 4
H.
Opioid: A medication or drug that is derived from the opium poppy or that mimics the effect of an opiate. 
Opiate drugs are narcotic sedatives that depress the activity of the central nervous system; these will 
reduce pain, induce sleep, and in overdose, will cause people to stop breathing. First responders often 
encounter Opioids and opiates in the form of morphine, methadone, codeine, heroin, fentanyl, oxycodone 
(OxyContin®, Percocet®), and hydrocodone (Vicodin®). 
I.
Opioid Antagonist: A drug that nullifies in whole or in part, and blocks the effects of, an Opioid by attaching 
to the Opioid receptors in the brain.  Includes the generic Naloxone and brand names such as nasal 
NARCAN®.
J.
Opioid Overdose: An acute condition including, but not limited to, extreme physical illness, decreased 
level of consciousness, respiratory depression, coma, or death resulting from the consumption or use of 
an Opioid or another substance with which an Opioid was combined, or that a layperson would 
reasonably believe to be an Opioid-related drug overdose that requires medical assistance.
K.
Participants: The pre-identified County employees, contractors and non-employee volunteers who will 
Possess Naloxone Kits or have quick access to Naloxone for overdose response on a volunteer basis. 
Once trained, these individuals will have the ability to Administer Naloxone to someone experiencing an 
overdose. 
L.
Program Coordinator: An employee designated by Maricopa County Department of Public Health. The 
Program Coordinator shall maintain and coordinate the County’s Naloxone Program, which will include 
but is not limited to, coordination of training of County Participants; maintaining records of Naloxone 
distribution to Departments for County Participants, and performing all other duties deemed necessary 
for successful implementation of the program. 
M. Possess: To have physical control or custody of an Opioid Antagonist such as nasal NARCAN® or 
other Naloxone formulation. 
IV. POLICY
It is the policy of Maricopa County that County employees, contractors, and non-employee volunteers who 
Possess or Administer Opioid Antagonists, such as nasal NARCAN® or other Naloxone formulations, are 
properly trained in the use and deployment of the medication and Administer or distribute the medication in 
accordance with A.R.S. §36-2267 and this policy. This policy applies to nasal NARCAN® or Naloxone that 
will be supplied to Maricopa County employees, contractors, and volunteers who Possess this medication 
during work hours, referred to as Participants. 
Arizona State law allows any person to Possess an Opioid Antagonist and protects individuals who 
Administer Opioid Antagonists from civil liability, criminal prosecution, or professional disciplinary actions 
because of the Possession or administration of the Opioid Antagonist if actions are taken in good faith. 
NALOXONE PROGRAM
The Naloxone Program allows trained Participants to Possess Naloxone Kits or have quick access to 
Naloxone for overdose response. Participants will have the ability to voluntarily Administer Naloxone to 
someone experiencing an overdose. Participating departments shall follow the instructions included in the 
“Opioid Overdose and Response” training module.  All staff that are part of implementation of any aspect of 
the Naloxone Program shall be trained in: 1) how to recognize an overdose; 2), how to respond to an 
overdose, including NARCAN® administration; and 3) calling for emergency services and 911. 
V. PROCEDURES
A. Training

Policy Number:
A1150
Policy Title:
NALOXONE PROGRAM
Current Adoption Date:
MM-DD-YYYY
Page 3 of 4
1.
Prior to issuance of NARCAN® (Naloxone HCI) Nasal Spray Kits to voluntary Participants for the 
purpose of Participant administration, Participants shall be trained in Opioid Overdose recognition 
and administration of the NARCAN® Nasal Spray. 
2.
Participants must complete the “Opioid Overdose and Response” online training module through 
Workday and read the orientation manual and materials.
3.
Participants who successfully complete training will be provided with a certificate of completion. To 
remain current, Participants must complete refresher training annually. 
B. Ordering Naloxone 
1.
MCDPH will be responsible for ordering Naloxone for the County Naloxone Program. 
2.
Department and/or Office Designees will order Naloxone using the internal Naloxone order form 
(Appendix A) provided by MCDPH. 
3.
Department Designees should ensure that they order Naloxone within 30 days of running out of 
supply. 
C. Delivery and Storage of Naloxone 
1.
MCDPH will receive and store Naloxone according to manufacturer’s recommendations and re-
package the NARCAN® Nasal Spray in a clearly marked NARCAN® Nasal Spray Kits 
2.
Each Maricopa County department should select a designee who can pick-up the Naloxone Kits from 
MCDPH once they are informed that their order is ready for pick-up. 
3.
MCDPH will keep a log of all Naloxone Kit distributions including the date and time of pick-up, the 
number of Kits included, and the department name and point of contact to which the Kits were 
distributed. 
4.
Department Designees will determine which Participants should receive the Naloxone Kits if there is 
a limited supply and should prioritize placing Kits at public facing sites where multiple Participants 
can access the Naloxone to respond to an overdose.
5.
Trained Participants that have volunteered to Administer Naloxone should ensure that Naloxone is 
always carried with them or is in a location that is easy to access. Naloxone should be stored at room 
temperature and should be protected from direct sunlight. 
6.
Each department distributing Naloxone must store the Kits following the storage instructions and 
procedures outlined in the Naloxone Program manual. 
7.
Each department and Participant issued a Naloxone Kit will be responsible for monitoring expiration 
dates of the Naloxone in its Possession. Department Designees should report to the Program 
Coordinator six months prior to expiration. 
D. Documentation 
1.
Each Department Designee will be responsible for keeping Naloxone Program logs as per the 
Naloxone Program manual and departmental procedures. 
2.
Each department will share the log with the MCDPH Program Coordinator monthly following the 
procedure outlined in the Naloxone Program manual.

Policy Number:
A1150
Policy Title:
NALOXONE PROGRAM
Current Adoption Date:
MM-DD-YYYY
Page 4 of 4
3.
The MCDPH Program Coordinator will maintain a record of all departments/Offices issued a 
Naloxone supply, Participants who have completed training, and Participants issued a NARCAN® 
Nasal Spray Kit.  
VI. Roles and Responsibilities
A.
The Maricopa County Department of Public Health will be responsible for the following: 
1.
Ordering and storing Naloxone and distributing to departments upon request. 
2.
Developing, maintaining, and implementing Naloxone training. 
3.
Developing educational and communication materials for the Naloxone Program. 
4.
Monitoring Naloxone supply. 
5.
Evaluating the Naloxone Program, including collection of Key Performance Indicators (KPIs) from 
departments. 
6.
Reporting on the Naloxone Program.  
7.
Assessing departments for implementation of the Naloxone Program. 
8.
Supporting departments in the development of departmental procedures. 
B.
County departments participating in the Naloxone Program are responsible for the following:
 
1.
Ensuring that Participants complete required training and maintain a record of all Participants who 
have received training. The records will be maintained and provided to the Program Coordinator. 
2.
Maintaining a log of Naloxone Kits received from MCDPH and distributing to Participants. 
3.
Completing incident reports in alignment with organizational policy. 
4.
Ordering Naloxone Kits as needed. 
5.
Monitoring expiration date of Naloxone. 
6.
Ensuring proper storage of Naloxone Kits.
C.
Participants will be responsible for:
1.
Completing all required training before Possessing or Administering a Naloxone Kit.
2.
Using good faith judgment before Administering a Naloxone Kit. 
3.
Not receiving any direct compensation for Possessing or Administering a Naloxone Kit.
4.
Participants may Possess and Administer a Naloxone Kit obtained through the Naloxone Program 
during non-work hours but must complete an incident report the following business day.
5.
Monitoring expiration date of Naloxone Kits and coordinating with their Department Designee to 
obtain a current supply.
6.
Ensure proper storage of Kits. 
Revision History
Version
Revision Date
Description of Revision
1
MM-DD-YYYY
Initial version. (C-##-##-###-#-##)